News, Publications & Awards — Selecta Biotech SE

Milestone10 Dec 2025

From Vision to Trials: Seven Years of Bold Science, One Mission Taking Shape

Reflecting on the journey from the idea that started it all to therapies moving toward the clinic.

Read story →

Events24 Nov 2025

MEDICA 2025 Reflections: Where Innovation Meets Purpose

Reflections from Düsseldorf, where encounters with clinicians, innovators and partners brought new perspective, pride and renewed belief in what our science can make possible for patients.

Read story →

Programme13 Nov 2025

PROTECT & GROW 2025

Celebrating innovation and legacy with Brichta & Partners – strengthening our research, IP and growth strategy.

Read story →

Perspective23 Oct 2025

Reflections on the OTS Annual Meeting 2025

Notes from the Oligonucleotide Therapeutics Society – a field in motion, and a community increasingly connected by the possibilities ahead.

Read story →

A view from the frontier.

Recent stories.

From Vision to Trials: Seven Years of Bold Science, One Mission Taking Shape

MEDICA 2025 Reflections: Where Innovation Meets Purpose

PROTECT & GROW 2025

Reflections on the OTS Annual Meeting 2025

Peer-reviewed science.

Therapeutic oligonucleotide ASC1R shows excellent tolerability and remarkable efficacy in reducing SARS-CoV-2 mRNA levels in C57BL/6 mice

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys

Plate reader spectroscopy as an alternative to atomic absorption spectroscopy for the assessment of nanoparticle cellular uptake

Effective reduction of SARS-CoV-2 RNA levels using a tailor-made oligonucleotide-based RNA inhibitor

Differences in surface chemistry of iron oxide nanoparticles result in different routes of internalization

Surface coating determines the inflammatory potential of magnetite nanoparticles in murine renal podocytes and mesangial cells

Chronic myelogenous leukemia on target

Selective therapeutic intervention: A challenge against off-target effects

Gene expression patterns as predictive biomarkers in hematology-oncology: Principal hurdles on the road to the clinic

Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia

In the press.

ESiNAR-X – Precise action in the treatment of leukaemia

A tailor-made antiviral therapy for SARS-CoV-2

Introducing a new generation of inhibitors to the oligonucleotide therapeutics market

Young biotechnology company of the year

Best MedTech innovation of the year – EU

The Slovak medicine for COVID-19 is heading to the Medicines Agency

Recognition & credentials.

Best innovation in medical technology

Innovation voucher 2023

Young biotechnology company of the year

Best MedTech innovation of the year – EU

ISO 9001

Follow our progress.